Recommendations for the management of critically ill patients with COVID-19 in Intensive Care Units.

COVID-19 COVID-19 Testing COVID-19 drug treatment Critical care Críticos Intensive Care Units Prueba de COVID-19 SARS-CoV-2 Tratamiento farmacológico de la COVID-19 Unidades de Cuidados Intensivos

Journal

Medicina intensiva
ISSN: 2173-5727
Titre abrégé: Med Intensiva (Engl Ed)
Pays: Spain
ID NLM: 101717568

Informations de publication

Date de publication:
02 2022
Historique:
received: 24 08 2021
accepted: 28 08 2021
pubmed: 15 12 2021
medline: 9 2 2022
entrez: 14 12 2021
Statut: ppublish

Résumé

The COVID-19 pandemic has led to the admission of a high number of patients to the ICU, generally due to severe respiratory failure. Since the appearance of the first cases of SARS-CoV-2 infection, at the end of 2019, in China, a huge number of treatment recommendations for this entity have been published, not always supported by sufficient scientific evidence or with methodological rigor necessary. Thanks to the efforts of different groups of researchers, we currently have the results of clinical trials, and other types of studies, of higher quality. We consider it necessary to create a document that includes recommendations that collect this evidence regarding the diagnosis and treatment of COVID-19, but also aspects that other guidelines have not considered and that we consider essential in the management of critical patients with COVID-19. For this, a drafting committee has been created, made up of members of the SEMICYUC Working Groups more directly related to different specific aspects of the management of these patients.

Identifiants

pubmed: 34903475
pii: S2173-5727(21)00179-X
doi: 10.1016/j.medine.2021.11.019
pmc: PMC8664080
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

81-89

Informations de copyright

Copyright © 2021 Elsevier España, S.L.U. and SEMICYUC. All rights reserved.

Auteurs

P Vidal-Cortés (P)

Medicina Intensiva, Complexo Hospitalario Universitario de Ourense, Ourense, Spain. Electronic address: pablo.vidal.cortes@sergas.es.

E Díaz Santos (E)

Medicina Intensiva, Consorci Corporació Sanitaria Parc Taulí, Sabadell, Spain; Departament de Medicina, Universidad Autónoma de Barcelona, Barcelona, Spain.

E Aguilar Alonso (E)

Medicina Intensiva, Hospital Universitario Reina Sofía, Córdoba, Spain.

R Amezaga Menéndez (R)

Medicina Intensiva, Hospital Universitari Son Espases, Palma de Mallorca, Spain.

M Á Ballesteros (MÁ)

Medicina Intensiva, Hospital Universitario Marqués de Valdecilla, Santander, Spain; Instituto de Investigación Valdecilla (IDIVAL), Santander, Spain.

M A Bodí (MA)

Medicina Intensiva, Hospital Universitario Joan XXIII, Tarragona, Spain; Universitat Rovira i Virgili, Tarragona, Spain.

M L Bordejé Laguna (ML)

Medicina Intensiva, Hospital Universitario Germans Trias i Pujol, Badalona, Spain.

J Garnacho Montero (J)

Medicina Intensiva, Hospital Virgen Macarena, Sevilla, Spain.

M García Sánchez (M)

Medicina Intensiva, Hospital Virgen Macarena, Sevilla, Spain.

M López Sánchez (M)

Medicina Intensiva, Hospital Universitario Marqués de Valdecilla, Santander, Spain.

I Martín-Loeches (I)

Intensive Care Medicine, St James's Hospital, Dublin, Ireland; Trinity College Dublin, School of Medicine, Dublin, Ireland.

A Ochagavía Calvo (A)

Medicina Intensiva, Consorci Corporació Sanitaria Parc Taulí, Sabadell, Spain.

P Ramírez Galleymore (P)

Medicina Intensiva, Hospital Universitari i Politècnic La Fe, Valencia, Spain.

S Alcántara Carmona (S)

Medicina Intensiva, Hospital Universitario Puerta de Hierro, Majadahonda, Spain.

D Andaluz Ojeda (D)

Medicina Intensiva, Hospital Universitario HM Sanchinarro, Madrid, Spain.

O Badallo Arébalo (O)

Medicina Intensiva, Hospital Universitario de Cruces, Bizkaia, Spain.

H Barrasa González (H)

Medicina Intensiva, Hospital Universitario de Áraba, Vitoria, Spain.

M Borges Sa (M)

Medicina Intensiva, Hospital Universitario Son Llátzer, Palma de Mallorca, Spain.

Á Castellanos-Ortega (Á)

Medicina Intensiva, Hospital Universitari i Politècnic La Fe, Valencia, Spain.

Á Estella (Á)

Medicina Intensiva, Hospital Universitario de Jerez, Jerez, Spain; Departamento de Medicina, INIBICA, Universidad de Cádiz, Cádiz, Spain.

R Ferrer Roca (R)

Medicina Intensiva, Hospital Universitario Vall d'Hebron, Barcelona, Spain.

V Fraile Gutiérrez (V)

Medicina Intensiva, Hospital Universitario Río Hortega, Valladolid, Spain.

M Fuset Cabanes (M)

Medicina Intensiva, Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain.

C Giménez-Esparza Vich (C)

Medicina Intensiva, Hospital Vega Baja Orihuela, Alicante, Spain.

C González Iglesias (C)

Medicina Intensiva, Hospital de Barbastro, Huesca, Spain.

A Hernández-Tejedor (A)

SAMUR-Protección Civil, Madrid, Spain.

J C Igeño Cano (JC)

Medicina Intensiva, Hospital San Juan de Dios, Córdoba, Spain.

D Iglesias Posadilla (D)

Medicina Intensiva, Hospital Universitario de Cruces, Bizkaia, Spain.

J J Jiménez Rivera (JJ)

Medicina Intensiva, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain.

C Llanos Jorge (C)

Medicina Intensiva, Hospital QuirónSalud Tenerife, Tenerife, Spain.

J A Llompart-Pou (JA)

Medicina Intensiva, Hospital Universitari Son Espases, Palma de Mallorca, Spain; Institut d'Investigació Sanitària Illes Balears (IdISBa), Palma de Mallorca, Spain.

V López Camps (V)

Medicina Intensiva, Hospital de Sagunto, Sagunto, Spain.

C Lorencio Cárdenas (C)

Medicina Intensiva, Hospital Universitario Doctor Josep Trueta, Girona, Spain.

P Marcos Neira (P)

Medicina Intensiva, Hospital Universitario Germans Trias i Pujol, Badalona, Spain.

M C Martín Delgado (MC)

Medicina Intensiva, Hospital Universitario de Torrejón, Torrejón de Ardoz, Spain; Universidad Francisco de Vitoria, Madrid, Spain.

M Martín-Macho González (M)

Medicina Intensiva, Hospital Virgen del Puerto, Plasencia, Spain.

L Martín Villén (L)

Medicina Intensiva, Hospital Universitario Virgen del Rocío, Sevilla, Spain.

X Nuvials Casals (X)

Medicina Intensiva, Hospital Universitario Vall d'Hebron, Barcelona, Spain.

A Ortiz Suñer (A)

Medicina Intensiva, Hospital Arnau de Vilanova, Valencia, Spain; Facultad de Medicina y Ciencias de la Salud, Universidad Católica de Valencia, Valencia, Spain.

M Quintana Díaz (M)

Medicina Intensiva, Hospital Universitario La Paz, Madrid, Spain; Departamento de Medicina Universidad Autónoma de Madrid, Madrid, Spain.

P Rascado Sedes (P)

Medicina Intensiva, Complexo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, Spain.

M Recuerda Núñez (M)

Medicina Intensiva, Hospital Universitario Puerto Real, Cádiz, Spain.

L Del Río Carbajo (L)

Medicina Intensiva, Complexo Hospitalario Universitario de Ourense, Ourense, Spain.

M Rodríguez Aguirregabiria (M)

Medicina Intensiva, Hospital Universitario La Paz, Madrid, Spain.

A Rodríguez Oviedo (A)

Medicina Intensiva, Hospital Universitario Joan XXIII, Tarragona, Spain.

I Seijas Betolaza (I)

Medicina Intensiva, Hospital Universitario de Cruces, Bizkaia, Spain.

C Soriano Cuesta (C)

Medicina Intensiva, Hospital Universitario Ramón y Cajal, Madrid, Spain.

B Suberviola Cañas (B)

Medicina Intensiva, Hospital Universitario Marqués de Valdecilla, Santander, Spain.

C Vera Ching (C)

Medicina Intensiva, Hospital Universitario Doctor Josep Trueta, Girona, Spain.

Á Vidal González (Á)

Medicina Intensiva, Fundación Jiménez Díaz, Madrid, Spain.

L Zapata Fenor (L)

Medicina Intensiva, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.

R Zaragoza Crespo (R)

Medicina Intensiva, Hospital Universitario Doctor Peset, Valencia, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH